Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)

Reports Q3 revenue $13.365M, consensus $7.86M. “Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue. During the third quarter, we shared initial preclinical data on our Voyager NeuroShuttle, a nonviral delivery platform with differentiated pharmacokinetics from transferrin receptor shuttle approaches. We are now introducing our first NeuroShuttle program,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Additionally, Voyager entered into a collaboration with Transition Bio in which we will have an option to license Transition Bio’s small molecules for ALS and FTD. TDP-43 appears to play a pivotal role in the pathophysiology of the vast majority of ALS cases, yet has been historically considered undruggable. We believe Transition Bio’s innovative biomolecular condensate approach may be able to unlock this critical target, and we are excited to contribute our neurotherapeutics expertise to this endeavor while continuing to prioritize maintaining our cash runway into 2028.”